Import License for Medical Devices in Philippines: Which LTO You Actually Need, and What to Do Without a Local Company

Import License for Medical Devices in Philippines: There Is No Standalone Import Permit

There is no single document called an import license for medical devices in Philippines. What actually lets you bring devices in is a Philippine FDA License to Operate (LTO) held by a local company for the activity it performs, plus a product-level authorisation for each device — a CMDN notification or a registration certificate, the one the trade calls the CPR. Anyone offering to sell you “the import licence” is describing one of those two, or neither.

Two layers, stacked, and they are not interchangeable:

• Company layer — the LTO. It says who may handle regulated health products in the Philippines and which activity that party may perform. It attaches to a Philippine-registered legal entity with a real, inspectable address. It does not attach to a product, and it cannot be issued to a foreign manufacturer that has no presence here.
• Product layer — CMDN or registration (CPR). It says which devices that licensed company may place on the market. It is filed by the LTO holder, in the LTO holder’s name, and it is only as wide as the models and catalogue numbers written into it.

Order matters and it is not negotiable: the company licence comes first, because on every product file the applicant is the licence holder. A dossier with no LTO behind it has nobody to file it. The risk class of your device then decides which product route you take — notification or full registration — and that logic is set out in our guide to the A/B/C/D device classes.

The third thing people miss: neither layer is a customs document. Even with both in hand, a regulated consignment still has to be released at the port against your standing authorisations, with the licensed entity named as consignee. Licensing gets you the right to sell; it does not by itself get the box off the wharf.

Medical Device Import Licenses in Philippines: What Importer, Distributor, Wholesaler and Trader Each Let You Do

The medical device import licenses in Philippines are not separate certificates — they are activity types declared on one LTO, and the activity you declare is the hard ceiling on what you may legally do. Declare “wholesaler” and you may not import. Declare “importer” and you still need a route to market. Getting this wrong is the most common reason a company finds out, mid-shipment, that its licence does not cover the thing it is doing.

The activity labels the FDA uses on device and IVD licences follow this logic. Confirm the exact wording against the application checklist in force on your filing date — the FDA revises its forms and circulars, and the label on the form is what binds you:

• Importer — brings regulated devices into the Philippines from abroad, in its own name, as the party on record for the entry. This is the activity that makes you the consignee Customs will accept. Importing is not the same as selling onward; most importers also carry a distribution activity.
• Distributor / Wholesaler — sells onward in bulk to hospitals, laboratories, clinics, dealers and retailers, but does not by itself authorise bringing goods in from abroad. A pure wholesaler buys from a licensed local importer. This is why “my distributor is licensed” is not an answer to “who imports?”
• Exporter — ships regulated products out of the Philippines. Relevant if you assemble, repack or consolidate here for regional supply.
• Trader — owns the product commercially, contracts a licensed manufacturer to make it, sets the specifications, and sells it through licensed distributors without operating a factory. This is the natural fit for brand owners who outsource production, and it is routinely confused with “distributor”.
• Manufacturer — makes, assembles, sterilises, repacks or relabels the device in the Philippines. Repacking and relabelling are the traps: they look like logistics and are treated as manufacturing.
• Retailer — sells directly to the end user. A separate question from all of the above and often overlooked by companies planning a direct-to-clinic model.

Three practical rules that follow from this:

• Activities can be combined on one licence, but each has to be declared. Importer plus wholesaler is the ordinary shape for a company that brings its own goods in and sells them onward. What you cannot do is declare the cheap activity and perform the expensive one.
• The licence is inspected against a physical reality. Premises, storage conditions, quarantine and rejected-goods areas, documentation and traceability, and a designated qualified person responsible for regulatory matters. A virtual office does not survive this.
• Scope changes are filed, not assumed. Adding an activity, changing address or changing the qualified person are variations to be reported and approved. Warehouse moves are the ones people forget until an inspector arrives at an empty unit.

License to Distribute IVDs in Philippines: Where the IVD Side Diverges

A license to distribute IVDs in Philippines is the same instrument as the device one — an FDA License to Operate carrying a distribution activity — but the FDA reads your scope, your storage and your product file by IVD-specific rules. There is likewise no separate import license for IVDs in Philippines: the importer activity on the LTO is what covers bringing kits in.

So the paperwork looks familiar and the substance is not. Four places where an IVD programme diverges from a general device programme:

• Classification runs on its own rules. Under the ASEAN Medical Device Directive framework the Philippines follows, IVDs are classified by IVD criteria — what follows a wrong result, whether there is a public-health dimension, whether a layperson reads the result — not by the general-device rules. A Class B kit and a Class B instrument reached the same letter by unrelated reasoning. The detail sits in our IVD classification and registration guide.
• Cold chain is a licensing issue, not a logistics issue. If your kits need controlled temperature, the establishment inspection behind the LTO will look at storage capacity, monitoring, calibration records, alarm handling and the excursion procedure. Distributors that only ever handled dry goods commonly fail here, and the failure surfaces during inspection rather than at the port.
• The product file is a different animal. Analytical and diagnostic performance, cut-offs, reference intervals, stability and shelf life — none of which appear in an implant dossier. A distributor who has never assembled an IVD file will lean on you for every one of these.
• The scope is a system, not an object. Reagents, calibrators, controls, consumables and the analyser they run on frequently belong in one commercial conversation but not in one filing line. Get the scope of what the distributor is licensed and registered to handle written down before the first order, model by model.

The distributor-selection consequence: a partner licensed and experienced in general devices is not automatically a safe pair of hands for diagnostics. Ask for the actual LTO document, check the activities and the product lines on it, and ask which IVD registrations they currently hold in their own name. “We do medical devices” is not an answer.

No Philippine Company Yet? Three Legal Routes In — and What Each Costs You in Control

A foreign manufacturer cannot hold a Philippine LTO. If you have no local entity, a licensed Philippine party has to stand in front of the FDA and Customs for you — and the three ways of arranging that differ mainly in who ends up owning your registration.

• Route 1 — appoint a local distributor who holds the licence and the registration. Fastest to market and cheapest to start: they already have the LTO, the warehouse and the customers. The cost is that the product authorisation sits in their name. If the relationship ends, your market access ends with it unless you negotiated otherwise at the start. See how to find and vet a Philippine distributor.
• Route 2 — a licensed third party imports on your behalf while you keep your own commercial footing. A licensed importer acts as the party of record for the entry and the tax, letting you test the market in small volumes without incorporating. It solves the who imports question, not the who is registered question — the product authorisation still has to sit under somebody’s licence. The mechanics are in our guide to the importer of record.
• Route 3 — incorporate, then get your own LTO. Slowest and most expensive to start, and the only route where the licence, the registration and the customer relationships are all yours. Companies that expect to be here in five years usually end up doing this, and the ones that planned for it from the start avoid a painful migration later.

How to choose, in one question: is this a market test or a market entry? A test tolerates someone else holding the paper. An entry does not — and the migration from Route 1 to Route 3 is the expensive part, because it involves prying a registration out of a partner who has no incentive to hand it over. Decide before you sign, not after the product sells.

Deciding who should hold the licence — you, an importer, or your distributor — before the first shipment? → talk it through with our product access team

The Letter of Authorisation: The Clause That Decides Who Keeps Your Market

The Letter of Authorisation (LOA) is what turns your foreign manufacturing entity into an acceptable source of the product in the eyes of the Philippine FDA — and, if drafted lazily, the document that quietly hands your market access to your distributor. It is a regulatory instrument, and it should not be buried inside the commercial distribution agreement.

Twelve things a workable LOA settles. The first six the FDA cares about; the last six are the ones you will wish you had when the relationship sours:

• Full legal identity of both parties — registered names and addresses as they appear on the corporate documents, not trading names.
• Product scope, model by model — device names, models, catalogue or reference numbers, kit sizes. A scope narrower than your catalogue means every new SKU needs a fresh letter.
• Territory — the Philippines, stated explicitly; regional letters get queried.
• Term and renewal — an LOA that expires mid-registration is a self-inflicted deficiency.
• Express authority to file with the FDA — to apply for, hold and maintain the product authorisation on your behalf.
• Signature, notarisation and legalisation — signed by an officer who demonstrably has the authority, then notarised and apostilled (or consularised, depending on the origin country and the practice in force). Documents come back for authentication defects more often than for substance.
• Exclusive or non-exclusive — and if exclusive, tied to performance, not to time alone.
• What happens to the registration on termination — the single most valuable clause in the document. An express undertaking to consent to transfer, to issue a no-objection letter, or to withdraw the filing on request.
• No sub-appointment without consent — otherwise your product can end up two tiers away from anyone you have vetted.
• Vigilance, complaints, field actions and recall duties — who reports what, to whom, in what time, and the obligation to pass reports back to you.
• Cooperation after termination — a defined wind-down window covering documents, stock, labelling and the regulatory handover.
• The supporting certificates that travel with it — a Certificate of Free Sale or equivalent from the country of origin, quality-system certificates, and manufacturer declarations, with the versions and validity you will actually be asked for.

Keep two documents, not one. The LOA is filed with a regulator and read by an evaluator; the distribution agreement carries pricing, targets, minimum volumes, payment and dispute resolution and stays private. Merging them means either handing commercial terms to a government file or writing a regulatory letter too vague to be useful. Draft them together, sign them together, keep them apart.

Changing Distributors: Who Owns the Registration, and How It Moves

The product authorisation belongs to the LTO holder that filed it — not to you as the manufacturer. If your distributor filed it, changing distributors does not move the certificate automatically, and nothing in your commercial contract obliges the FDA to treat it as yours.

What that means in practice when you want to switch:

• You need the outgoing holder’s cooperation, or a clause that manufactures it. Withdrawal of your LOA is the lever you hold; a no-objection or consent letter is what the incoming holder generally needs. A partner who is losing the business has every reason to be slow. This is why the termination clause in the LOA is worth more than the exclusivity clause.
• Plan for a re-filing timeline, not a paperwork afternoon. Whether a change of holder is processed as a transfer or requires the new licence holder to file afresh has varied with the circular in force — confirm the current route before you commit to a date. Budget as if it were a new filing and treat anything faster as upside.
• Watch the gap. Between the old registration lapsing or being withdrawn and the new one issuing, your product may have no valid authorisation — which means no imports, and stock already in country in an awkward position. Sequence the switch so the new holder is in place before the old one is dismantled, and time it against your inventory cover.
• Do it in writing, to everyone. Withdraw the LOA formally, notify the FDA in the manner the current rules require, and tell your hospital and laboratory customers who they will be buying from and when. Silence here is what turns a routine change into a rumour that you are leaving the market.
• Don’t forget the physical stock. Product already released under the old holder’s name, product in their warehouse, and labelling and inserts naming them as the local representative all need a decision — relabelling is a manufacturing-type activity and cannot simply be done in a back room.

The cheapest version of this problem is the one you prevent. If there is any chance you will change partners, either hold the registration yourself through your own licensed entity, or write the release mechanism into the LOA before the first shipment.

How the Licence Meets Customs at the Port

A valid LTO and a valid product authorisation do not by themselves release a container. Regulated health goods are cleared at shipment level against your standing authorisations, and the consignee named on the entry has to be the licensed entity. Mismatch there is the most ordinary reason a first shipment sits at the port.

• Consignee = licence holder. If the bill of lading names your foreign company, your freight forwarder, or a related company without the licence, the entry does not line up with the authorisation. Fix the shipping documents before the vessel sails, not after.
• The product on the invoice must be the product on the authorisation. Model numbers, kit sizes and pack configurations that do not match what was registered will be questioned, and “it’s essentially the same item” is not a customs argument.
• Storage and demurrage run from arrival. They do not wait for you to find the missing document, and they land on the importer of record. A week of paperwork chasing can cost more than the compliance work you skipped.
• Admissibility is the importer’s legal problem. Under the Customs Modernization and Tariff Act framework, the importer of record answers for valuation, tariff classification, origin and whether the goods were admissible at all — including whether the required health-product authorisations existed. See which goods need a permit and from which agency and the clearance process end to end.
• If it is already held, the clock is against you. The recovery path depends on why it stopped — documentation, valuation, classification, or a missing authorisation that cannot be cured retroactively. What to do when your shipment is held covers the triage.

Sequence, Cost, and the Five Mistakes That Reset the Clock

Run it in this order: decide who will hold the licence → have that entity registered and premises ready → LTO → classify the device or IVD — assemble the product file → CMDN or registration → then, and only then, ship. Every expensive story in this business is a version of doing step six before step three.

The five mistakes that cost the most time:

• Shipping before the product authorisation exists, on the assumption it will be issued while the goods are in transit. Storage charges accrue against a container that may not be releasable at all.
• Declaring the wrong activity on the LTO — typically wholesaler when the business model requires importer — and discovering it at the port.
• Letting the distributor be the registrant with no release clause, then finding the exit costs more than the partnership ever earned.
• An LOA narrower than the catalogue, so that every new model restarts the legalisation cycle from the head office.
• Letting the LTO or the registration lapse. Renewal windows are administrative, unforgiving, and easy to miss when the person who filed it has left the company.

On cost and timeline, be suspicious of precision. FDA fees are set by a published schedule that is revised from time to time, and elapsed time depends on your risk class, the completeness of the file, the deficiency rounds and the inspection calendar — the clock stops while a file sits with you. Treat any consultant quoting a guaranteed approval date, or promising approval at all, as telling you something about themselves rather than about the process. Ask instead for the deficiency rate on files like yours and what happens to the fee if it comes back.

Disclaimer. This guide is general information on how Philippine device and IVD import licensing is structured; it is not legal or regulatory advice and it quotes no fee or processing time on purpose. Classification, activity definitions, documentary requirements, authentication practice and the transfer route all follow the FDA circulars and Bureau of Customs rules in force on your filing date — verify against the latest FDA issuances, and take individual professional advice for your product and transaction.